BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38016433)

  • 21. Comparison of 68Ga-PSMA PET/CT and mp-MRI in regard to local staging for prostate cancer with histopathological results: A retrospective study.
    Ucar T; Gunduz N; Demirci E; Culpan M; Gunel H; Kir G; Atis RG; Yildirim A
    Prostate; 2022 Nov; 82(15):1462-1468. PubMed ID: 35915579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PSMA-PET and micro-ultrasound potential in the diagnostic pathway of prostate cancer.
    Lopci E; Lughezzani G; Castello A; Colombo P; Casale P; Saita A; Buffi NM; Guazzoni G; Chiti A; Lazzeri M
    Clin Transl Oncol; 2021 Jan; 23(1):172-178. PubMed ID: 32447644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection Rate of
    Pepe P; Pepe L; Cosentino S; Ippolito M; Pennisi M; Fraggetta F
    Anticancer Res; 2022 Jun; 42(6):3011-3015. PubMed ID: 35641295
    [TBL] [Abstract][Full Text] [Related]  

  • 24.
    Pepe P; Pepe L; Tamburo M; Marletta G; Savoca F; Pennisi M; Fraggetta F
    In Vivo; 2023; 37(3):1318-1322. PubMed ID: 37103095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Performance of 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography in the diagnosis of primary prostate cancer: a systematic review and meta-analysis.
    Hu X; Wu Y; Yang P; Wang J; Wang P; Cai J
    Int Braz J Urol; 2022; 48(6):891-902. PubMed ID: 34003611
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lymph node staging with 68Ga-PSMA PET in patients with intermediate and high-risk prostate cancer suitable for radical prostatectomy managed in a prostate cancer unit.
    Maestroni UV; Campobasso D; Guarino G; Acampora A; Scarlattei M; Ziglioli F; Dinale F; Baldari G; Migliari S; Gasparro D; Ferretti S; Silini EM; Ruffini L
    Chin Clin Oncol; 2023 Jun; 12(3):22. PubMed ID: 37417288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients.
    Zang S; Shao G; Cui C; Li TN; Huang Y; Yao X; Fan Q; Chen Z; Du J; Jia R; Sun H; Hua Z; Tang J; Wang F
    Oncotarget; 2017 Feb; 8(7):12247-12258. PubMed ID: 28103574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunohistochemical Validation of PSMA Expression Measured by
    Woythal N; Arsenic R; Kempkensteffen C; Miller K; Janssen JC; Huang K; Makowski MR; Brenner W; Prasad V
    J Nucl Med; 2018 Feb; 59(2):238-243. PubMed ID: 28775203
    [No Abstract]   [Full Text] [Related]  

  • 29.
    Liu C; Liu T; Zhang Z; Zhang N; Du P; Yang Y; Liu Y; Yu W; Li N; Gorin MA; Rowe SP; Zhu H; Yan K; Yang Z
    J Nucl Med; 2020 Sep; 61(9):1314-1319. PubMed ID: 32034111
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual time point imaging of staging PSMA PET/CT quantification; spread and radiomic analyses.
    Aksu A; Vural Topuz Ö; Yılmaz G; Çapa Kaya G; Yılmaz B
    Ann Nucl Med; 2022 Mar; 36(3):310-318. PubMed ID: 34988888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 68Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer.
    Fendler WP; Schmidt DF; Wenter V; Thierfelder KM; Zach C; Stief C; Bartenstein P; Kirchner T; Gildehaus FJ; Gratzke C; Faber C
    J Nucl Med; 2016 Nov; 57(11):1720-1725. PubMed ID: 27261520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlations of
    Topuz ÖV; Aksu A; Erinç SR; Tamam MÖ
    Hell J Nucl Med; 2021; 24(1):60-65. PubMed ID: 33866340
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Yang J; Li J; Xiao L; Zhou M; Fang Z; Cai Y; Tang Y; Hu S
    Cancer Imaging; 2023 Sep; 23(1):81. PubMed ID: 37667341
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Findings in 1,123 Men with Preoperative
    Raveenthiran S; Yaxley WJ; Franklin T; Coughlin G; Roberts M; Gianduzzo T; Kua B; Samaratunga H; Delahunt B; Egevad L; Wong D; McEwan L; Brown N; Parkinson R; Esler R; Yaxley JW
    J Urol; 2022 Mar; 207(3):573-580. PubMed ID: 34694140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study.
    Emmett L; Buteau J; Papa N; Moon D; Thompson J; Roberts MJ; Rasiah K; Pattison DA; Yaxley J; Thomas P; Hutton AC; Agrawal S; Amin A; Blazevski A; Chalasani V; Ho B; Nguyen A; Liu V; Lee J; Sheehan-Dare G; Kooner R; Coughlin G; Chan L; Cusick T; Namdarian B; Kapoor J; Alghazo O; Woo HH; Lawrentschuk N; Murphy D; Hofman MS; Stricker P
    Eur Urol; 2021 Dec; 80(6):682-689. PubMed ID: 34465492
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of 68Ga-PSMA-PET/CT for the detection of primary prostate cancer prior to biopsy: a prospective study.
    Jain H; Sood R; Faridi MS; Goel H; Sharma U
    Cent European J Urol; 2021; 74(3):315-320. PubMed ID: 34729219
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 68Ga-PSMA PET/CT evaluation in men enrolled in prostate cancer Active Surveillance.
    Pepe P; Pepe L; Tamburo M; Marletta G; Savoca F; Pennisi M; Fraggetta F
    Arch Ital Urol Androl; 2023 May; 95(2):11322. PubMed ID: 37212907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ability of
    Yi N; Wang Y; Zang S; Yang L; Liu H; Sun H; Wang L; Wang F
    Cancer Med; 2023 Mar; 12(6):7140-7148. PubMed ID: 36519688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A prospective comparative study of [
    Gao X; Tang Y; Chen M; Li J; Yin H; Gan Y; Zu X; Cai Y; Hu S
    Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):2177-2187. PubMed ID: 36811661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.